Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- Personal Care Products
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1686
'Micro Implant Patents and Patent Applications' refers to United States patent Application Serial Number 07/232,671, an Application, allowed in part and issued on November 2, l993, as Patent No. 5,258,028, United States Patent for Textured Micro Implants
'Reflux Disorders Patent Application' refers to United States Patent Application Serial Number 07/863,848, entitled Treatment of Urologic and Gastric Fluid Reflux Disorders by Injection of Micro Particles
IPSCIO Record ID: 27711
IPSCIO Record ID: 963
MacroplastiqueÂ® is a minimally invasive, implantable soft tissue bulking agent for the treatment of urinary incontinence.
IPSCIO Record ID: 378
U.S. Patent 5,120,310, Issued June 9, 1992, entitled Nonreusable Syringe; U.S. Patent 5,188,613, Issued February 23, 1993, entitled Nonreusable Syringe with Safety Clip; U.S. Patent 5,267,961, Issued December 7, 1993, entitled Nonreusable Syringe with Safety Clip; Foreign Counterpart Patent Applications on the Nonreusable Syringe with Safety Clip corresponding to U.S. Patents 5,120,310 and 5,188,613 for Europe (Serial No. 92910361.2), China (Serial No. 92102245.X), India (Serial No. 186/CAL/92), Mexico (Serial No. 92-01493), and Taiwan (Serial No. 82205282); U.S. Patent 5,423,758, Issued June 13, 1995, Entitled Retractable Fluid Collection Device and a Counterpart Patent Cooperation Treaty Application Serial No. 94/13953, Entitled Blood Sampler, Filed December 6, 1994 designating all PCT countries; U.S. Patent 5,385,551, Issued January 31, 1995, Entitled Nonreusable Syringe with Front Retraction and a Counterpart Patent Cooperation Treaty Application Serial No. PCT/US94/10235, Filed September 7, 1994 designating all PCT countries; U.S. Patent 5,389,076, Issued February 14, 1995, Entitled Single Use Medical Device with Retraction Mechanism and a Counterpart Patent Cooperation Treaty Application Serial No. PCT/US95/03953, Filed March 31, 1995 designating all PCT countries; U.S. Patent Application Serial No. 380107, Filed January 30, 1995, Entitled Syringe Plunger Seal and Locking Assembly, and the right to file Patent Applications thereon in nearly any foreign country until January 30, 1996; and A new U.S. Patent Application filed in May, 1995, Entitled Tamperproof Retractable Syringe with Serial No. 08/438,954, and the right to file Patent Applications thereon in nearly any foreign country until May, 1996.
IPSCIO Record ID: 1704
IPSCIO Record ID: 5833
Licensed Product means any product or material distributed solely for use in the field of dermatology for application in the epidermis, dermis, or subcutaneous fatty tissue, urology, and gastroenterology the manufacture, use or sale of which by an unlicensed third party would constitute an infringement of a Valid Claim if such claim is or were to be included in an issued patent.
Patent Rights means all rights in U.S. patents 5,116,371 and 5,713,960.
The bulking agent that comprises our products involves the use of a polymeric component from the poly-n-vinyl pyrrolidinone (PVP) family, which is recognized for its biocompatibility and extensive clinical use in other Class III (permanent implantable) medical devices.
PVP is a non-toxic, non-metabolized hydrogel that has been approved for use as a plasma volume expander, a plasma detoxifying agent, an orally-ingested diagnostic aid (complex of PVP and iodine), a component of soft contact lenses, a variety of dental applications, a filler for a permanent implantable urological device and as an excipient in the manufacturing of tablets containing a variety of drugs. The dose of PVP used in our products is minimal; approximately 95% of the injected volume is water contained in the polymer matrix. We are developing the following products designed for use in dermatology, urology, and gastroenterology. Dermatology AquaDerm is targeted at the long-term corrective effects of skin treatment. AquaDerm addresses conditions of tissue atrophy due to aging, facial wrinkles and depressed scars, as well as soft tissue defects resulting from surgery and inflammatory skin diseases. PVP has infinite molecular weight as a base polymer matrix, which impedes absorption and migration of polymer substrate into the surrounding tissue, thus lengthening the cosmetic effect. Most other injectable materials are suspensions (leading to the absorption of suspension media and migration of suspended particles) or biological in nature (such as Collagen, which the body digests).
Our product will be injected into the affected areas and filled to the appropriate point, making the defect flush with the surrounding tissue, or in the case of lip augmentation plumped to the desired size. Most products in the facial aesthetics/dermatology market today have the common drawback of migration/absorption. Animal trials and initial human clinical trials indicate longer-term maintenance of results for AquaDerm. Urology AquaGen has been developed for use as a bulking agent in the minimally invasive treatment of stress urinary incontinence (SUI), the most common form of urinary incontinence. AquaGen is injected into the urethra/bladder junction (urinary sphincter muscle), reinforcing the muscle tissues around the bladder neck, the 'bulking' of the closure mechanism that prevents accidental urine leakage. Gastroenterology AquaFlux has been designed for use as a bulking agent in the minimally invasive treatment of chronic heartburn or gastroesophageal reflux disease (GERD). AquaFlux is utilized as a bulking agent to strengthen and build the sphincter muscle at the base of the esophagus through a minimally invasive procedure, reinforcing and augmenting the closure mechanism that prevents reflux or gastric heartburn.
IPSCIO Record ID: 29212
Licensed Patent Rights and Licensed Patents shall mean (1) United States Provisional Patent Application No. 60/698,748 filed July 13, 2005, and titled Suturing System for Transoral Gastroplasty and United States Provisional Patent Application No. 60/742,826 filed December 6, 2005, and titled Systems and Techniques for Transoral Gastroplasty; (2) International Patent Application No. PCT/US04/028516 entitled Suturing Devices and Methods, filed September 2, 2004 (claiming benefit of U.S. Provisional Patent Application Serial No. 60/499,539, filed September 2, 2003; U.S. Provisional Patent Application Serial No. 60/507,837, filed October 1, 2003; and U.S. Provisional Patent Application Serial No. 60/576,510, filed June 3, 2004); (3) any and all Patent Rights under the patents or patent applications for any Additional Technologies and associated Know-How licensed by the Company.
IPSCIO Record ID: 5337
U.S. Patent 4,955,909 September 11, 1190 (S.N. 07/496,234)
U.S. Patent 5,260,965 November 26, 1191 (S.N. 07/304,764)
U.S. Patent 5,997,574 and any corresponding foreign patent applications U.S. Patent 5,630,844 and any corresponding foreign patent applications U.S. Patent 6,162,251 and any corresponding foreign patent applications U.S. Patent 09/452,656 and any corresponding foreign patent applications.